Management Team

Andrew Hall, B. Med. Sci., M.Sc.

Chief Executive Officer

Andrew brings more than 20 years of executive experience in biopharmaceuticals and life science. He has spent his career focused on corporate and portfolio strategy, as well as business development and commercial operations with industry leaders such as Celgene, Merck, Schering-Plough and Bristol-Meyers Squibb, spearheading new product development, analytics and commercial strategy for immunology & inflammation, oncology, women's health, cardiovascular portfolios and more. In his most recent roles with Celgene, Andrew had led new product analytics and commercial strategy for the Inflammation & Immunology division and led new critical alliances across all therapeutic areas. He joined IMV as Chief Business Officer in 2020 and became the Company’s CEO in January 2021. Andrew Hall holds a Master of Science from RMIT University and a Bachelor of Medical Science with Honors from Melbourne University.

Jeremy Graff, PhD

Chief Scientific Officer

Dr. Graff brings over 20 years of experience in preclinical, translational research and clinical development for novel Cancer therapeutics and joined IMV in June 2021 as Chief Scientific Officer. Most recently, Dr. Graff served as Chief Development Officer and Senior Vice President, Research at HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis. At HiberCell, heled the scientific and clinical development teams. Prior to that he served as President and Chief Scientific Officer for Biothera Pharmaceuticals (2018-2020)starting Chief Scientific Officer (2014-2018). In these executive roles, Dr. Graff was responsible for the strategic design of the Biothera clinical program. He also led corporate strategy and investor engagement. Ultimately, he orchestrated the acquisition of Biothera and its lead asset, Imprime PGG, by HiberCell, Inc in 2020. Prior to leaping into Biotech, Dr. Graff spent nearly 17 years at Eli Lilly and Company, delivering multiple novel therapies to the clinic. His extensive experience in Cancer Drug Discovery and Development, immuno-oncology, biomarker discovery and patient stratification culminated in designing, developing and leading the Translational Oncology group Unit to improve the technical success of Lilly’s Oncology portfolio. At Lilly Research Labs (LRL), he was the recipient of the LRL President’s Recognition Award, the Company’s highest annual award. Dr. Graff received a Ph.D. from the University of Kentucky’s Markey Cancer Center and completed a post-doctoral fellowship at the John Hopkins University Oncology Center. He has authored more than 60 peer-reviewed publications that have collectively garnered more than 20,000 research citations and holds a number of patents for novel cancer therapies. He has also served for nearly a decade on the editorial board for Cancer Research, the flagship journal for the American Association for Cancer Research.

Brittany Davison, CPA, CA

Chief Accounting Officer

With over 10 years of financial reporting experience, Brittany has provided key financial and operational leadership to IMV since she began working for the company in February 2014. She is responsible for financial reporting, tax and securities compliance, managing audit and internal control functions, investor relations and IT oversight. Prior to joining the company, she began her career as an audit senior at Grant Thornton. Brittany graduated summa cum laude with a Bachelor of Commerce degree from Saint Mary’s University and is a Chartered Professional Accountant. Brittany volunteers with the Mental Health Foundation of Nova Scotia and is actively involved in the Atlantic Chapter of Financial Executives International.

Jennifer Schmitke, PhD

Acting Chief Operating Officer

Dr Schmitke brings over 20 years of experience in drug development and operations in organizations from early start ups to big biotech. Jen has deep experience in technical operations including all aspects of CMC as well as portfolio strategy and management. Most recently Jen was Senior Vice President, Technical Operations, Quality and Portfolio and Program Management at Epizyme, a commercial-stage biopharmaceutical oncology company focused on developing novel epigenetic medicines. Prior to Epizyme, Jen held roles of increasing responsibility in CMC/technical operations and portfolio strategy, leadership and management at multiple companies. Jen served at Magenta Therapeutics as Vice President Program Management where she drove the build out of the portfolio and program management functions and supporting governance. As the first Vice President and executive at Omega Therapeutics, Jen helped build the company and research pipeline from the ground up. Prior to Omega, Jen was a Sr Director at Biogen in early pipeline leadership and beforehand spent many years at Alkermes where, in addition to program leadership positions, she held a series of roles of increasing responsibility in technical development and CMC leadership. Over her career Jen gained experience across all phases of late discovery and development, as well as on in-market products. This included the development of Bydureon® for Type 2 diabetes through its successful approval, work on VIVITROL® approved for alcohol and opioid dependence, and clinical development of additional assets that are now approved. Jen earned her Bachelor of Science in Chemistry with honors from Queen’s University in Ontario, Canada and her PhD in Biological Chemistry from Massachusetts Institute of Technology.

Linda Barabé, MBA

Senior Vice President, Human Resources and Internal Communications

Linda brings 25 years of global Human Resources experience with a career encompassing both international and domestic responsibilities. She has held leadership roles in various industries, from Engineering and Retail to Technology and Pharmaceuticals. Before joining IMV Inc., Linda was the Vice President of Human Resources for Baylin Technologies. Linda’s industry experience and expertise lie in change management, leadership development, diversity/inclusion, talent acquisition, mergers and acquisitions, and divestitures. Linda earned a Master’s in Business Administration from Royal Roads University in British Columbia, specializing in Strategic Human Resource Management.  She also serves on the HR committee for St Raphael, a non-profit palliative care home providing services for terminally ill patients.

Marie-Eve Charrois, MA

Vice President, Regulatory Affairs and Pharmacovigilance

Marie-Eve is in charge of developing the regulatory dossier and obtaining the required authorization to achieve IMV’s clinical programs. She also oversees the pharmacovigilance and activities related to the clinical safety of the investigational products used in IMV sponsored clinical trials. She brings 25 years of experience in research and in the biopharmaceutical industry. She developed an expertise in supporting the clinical development and ensuring the regulatory compliance of several types of innovative biologics and licensed vaccines. During her 18-year experience at Medicago (a biotech company developing Virus-Like Particle vaccine), she has served in many roles of increasing responsibility in Research, Quality, and Regulatory Affairs, and the five last years as Director of Regulatory Affairs. As Site Conformance Manager at GSK Vaccine (Quebec City facility), she has played an active role in the development of regulatory strategies for the implementation of changes to the licensed manufacturing process and obtaining the necessary approval to allow the Seasonal Influenza vaccine to be released and delivered in time. She was also in charge of the preparation for GMP inspections by the GSK Global Quality organization and the Regulatory Agencies. Over her career, she was involved in the preparation of the regulatory dossier to support several Phase 1, 2, and 3 clinical trials conducted in Canada, USA, Europe, South Africa, and Australia. She has actively participated in formal and technical meetings with regulatory authorities (FDA, Health Canada BRDD, and EMEA) in the context of the vaccine development, and also in the context of regulatory interactions associated with the maintenance of licensed vaccines. Marie-Eve also successfully contributed to the development of the CMC/Quality sections of submission packages for license applications (BLA in US and NDS in Canada) and post-approval changes. More recently, she was selected in the first cohort of the Excellence in Canadian Board Governance (ECBG) Program from the McGill University Executive Institute and completed the program developed in collaboration with Executive Women in Bio (WIB - Greater Montreal). Marie-Eve also owns a Master of Arts from Laval University in Quebec.

Stéphan Fiset, MSc, MBA

Vice President, Clinical Research

Stephan manages the implementation and progress of IMV’s clinical programs since 2007. Prior to joining the company, he worked for more than 15 years in clinical research with Medicago, GlaxoSmithKline and the Infectious Disease Research Center of the CHUL, where he led multifunctional teams in several therapeutic areas, including Oncology, HIV, Vaccines, Sepsis, Hematology, and Neurology. Throughout his career, he was involved in scientific and operational activities of several Phase I to Phase III trials. He has also led several process improvement teams to ensure timely and cost-effective delivery of clinical trials. Stephan received an MBA with honor from Université Laval and a Master degree in Microbiology from the University of Sherbrooke.

Heather Hirsch, PhD

Vice President, Translational Research

Dr. Hirsch brings more than 10 years of expertise in translational sciences having worked at Merck, Jounce Therapeutics and most recently CRISPR Therapeutics. Heather has a strong background in immune-oncology, tumor microenvironment, and integrative translational analyses designed to inform indication selection, mechanism of action, and responder identification. Heather also brings strong expertise in computational biology and ‘omics level analyses. Throughout her career, Heather has been involved in many preclinical and clinical stage small molecule, biologics (including Keytruda), and cell therapy-based programs. She has led translational efforts across drug development stages from Target Identification through to phase III trials including driving companion diagnostic development. Heather holds a PhD in Cell and Molecular Biology from Michigan State University and completed post-doctoral fellowship at Harvard Medical School with much of her research focusing on gene expression regulation in cancer.